About Tolerion

Tolerion is a clinical-stage biopharmaceutical company using our proprietary therapeutic platform to develop a pipeline of novel products to treat autoimmune diseases in a fundamentally new manner.

Our product candidates are designed to selectively eliminate specific, harmful immune responses while leaving the rest of the immune system intact, a state known as “tolerance”. This targeted and selective approach will lead to improved efficacy, safety and tolerability relative to current therapies.

Currently there are no approved therapies that restore tolerance in autoimmune disease. Our lead product candidate, TOL-3021, for the treatment of type 1 diabetes, has completed a Phase 2a clinical trial.

Based on our discussions with FDA, we believe that our next trial for TOL-3021 could be a pivotal clinical trial. Our second product candidate, TOL-3034, for the treatment of myasthenia gravis, is in preclinical development. We own all worldwide marketing, distribution and manufacturing rights to each of our product candidates.

Tolerion Board of Directors

Team

Lawrence Steinman, MD

Founder and Executive Chairman
+

Dr. Steinman is a founder of Tolerion and is currently the George A. Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics in the Stanford University School of Medicine. From 2002 to 2011, Dr. Steinman chaired the Stanford University Program in Immunology. Research in his laboratory led to the development of the blockbuster drug Tysabri® (natalizumab), which is used to treat patients with the autoimmune diseases multiple sclerosis and Crohn’s Disease. He has received numerous awards for his research and has been elected to both the National Academy of Sciences and
the National Academy of Medicine.

Dr. Steinman served on the board of directors and headed the scientific advisory board at Centocor for ten years, until the company was acquired by Johnson & Johnson. Dr. Steinman also co-founded and served as a director of Atreca, Neurocrine Biosciences and Bayhill Therapeutics, and he co-founded Nuon Therapeutics. Dr. Steinman received a BA from Dartmouth College and an MD from Harvard University.

Team

Nigel Ray

Founder, President and CEO
+

Mr. Ray is a founder of Tolerion and has over 30 years of transactions, commercial operations, and marketing experience in pharmaceutical and biotechnology companies. Prior to Tolerion, Mr. Ray was Vice President of Global Licensing at Aptalis Pharmaceuticals. Previously, Mr. Ray led business development at Atreca, AcelRx Pharmaceuticals, Limerick Biopharma, and DURECT, and he led marketing at ALZA.

Mr. Ray received a BA in human biology from Stanford University and an MBA from the Anderson School of Business at the University of California, Los Angeles.

Team

Franklin Berger

 
+

Mr. Berger is a biotechnology industry analyst with over twenty-five years of experience in capital markets and financial analysis. Mr. Berger was most recently a founder of the small-cap focused NEMO Fund at Sectoral Asset Management. He previously served as Managing Director, Equity Research, and Senior Biotechnology Analyst at J.P. Morgan Securities. Mr. Berger served in similar capacities at Salomon Smith Barney and Josephthal & Co., and has been involved with the issuance of over $12 billion in biotechnology company equity or equity-linked securities, including the Genentech initial public offering.

Mr. Berger currently serves as a director of the public biotechnology companies Five Prime Therapeutics, Immune Design, and BELLUS Health, and he previously served as a director of public biotechnology companies Seattle Genetics, Aurinia Pharmaceuticals, and VaxGen. Mr. Berger received a B.A. in International Relations and an M.A. in International Economics from Johns Hopkins University, and an M.B.A. from Harvard University. He is a Founding Fellow of the Biotechnology Study Center at New York
University School of Medicine.

Team

William H Robinson, MD PhD

Founder
+

Dr. Robinson is a founder of Tolerion and is currently Associate Professor of Medicine in the Division of Immunology and Rheumatology of the Department of Medicine at Stanford University. Dr. Robinson is Director of the Stanford's Osteoarthritis Initiative and a co-lead of the Accelerating Medicines Partnership in Rheumatoid Arthritis and Lupus Network of the NIH. Dr. Robinson was elected to the American Society of Clinical Investigation (ASCI) and serves on the board of directors of Federation of Clinical Immunology Societies (FOCIS). He is an inventor on nineteen patent applications, and technologies developed in his Stanford and VA laboratories have been licensed to seven companies in the biotechnology industry.

Dr. Robinson was a co-founder of Bayhill Therapeutics and Atreca. Dr. Robinson received his BS, MD, and PhD degrees from Stanford University and completed his clinical training in internal medicine at the University of California, San Francisco.

Team

PJ Utz, MD

Founder
+

Dr. Utz is a founder of Tolerion and currently directs a lab of 8 scientists in the Department of Medicine, Division of Immunology at Stanford University School of Medicine. He is Director of Stanford's Medical Scientist Training Program and Director of Stanford’s Autoimmunity Center of Excellence (ACE). The Utz lab studies autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), scleroderma, myositis, primary biliary cirrhosis (PBC), Sjögren's disease, type I diabetes (T1D), vasculitis, multiple sclerosis (MS) and mixed connective tissue disease (MCTD). In addition to trying to better understand the pathogenic mechanisms involved in autoimmunity, the Utz lab is interested in developing bench-to-bedside technologies, including multiplexed diagnostics and therapeutics, for human immune diseases. Dr. Utz cofounded BayHill Therapeutics. Dr. Utz attended King’s College in Wilkes-Barre PA before he obtained his MD at Stanford and completed clinical training in Internal Medicine and Rheumatology at Brigham and Women’s Hospital at Harvard.

Team

Andy Lam, MD

 
+

Dr. Lam is an investor, physician, engineer, and entrepreneur. He is Co-Founder and Managing Partner at Uprising, a venture capital firm. He was on the founding investment team at PL Capital, a $300M fund, worked for the highest-performing hedge fund in the world, and has co-founded four technology companies. He received his MD from Baylor College of Medicine, and has a BS in Engineering from Stanford where he was a President’s Scholar.

Scientific Advisory Board

Dummy Img

Bruce Buckingham

Stanford University
Professor of Pediatrics

  • Diabetes research in children, particularly continuous glucose monitoring and immune intervention
  • Decade of clinical trial experience
Dummy Img

Stephen Gitelman

University of California San Francisco
Professor of Pediatrics

  • Research on cause for immune mediated destruction of insulin producing beta cells
  • TrialNet center director
  • Immune Tolerance Network investigator
Dummy Img

Kevan Herold

Yale University
Professor of Immunobiology and Medicine

  • TrialNet program leader
  • Part of team to 1st report use of anti-CD3 mAB
Dummy Img

John Lachin

George Washington University
Professor of Biostatistics and of Epidemiology

  • Principle investigator of Center for the Epidemiology of Diabetes Intervention (EDIC) study and Glycemic Reduction Approaches in Diabetes (GRADE)
Dummy Img

Darrell Wilson

Stanford University
Professor of Pediatrics, Chief of Division of Pediatric Endocrinology and Diabetes

  • Principal investigator of Stanford Center for NIH-funded Type-1 diabetes TrialNet group